| Literature DB >> 20207537 |
John F Miller1, Elizabeth M Turner, Kristjan S Gudmundsson, Stephen Jenkinson, Andrew Spaltenstein, Michael Thomson, Pat Wheelan.
Abstract
The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar anti-HIV activity. 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20207537 DOI： 10.1016/j.bmcl.2010.02.053
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823